BioWorld

Aug. 18, 2008

Cytos Signs $139M Deal with Pfizer for Immunodrug Vaccines

As three of its own Immunodrug vaccine candidates advance through clinical trials, Cytos Biotechnology AG signed a CHF150 (US$139 million) technology deal with Pfizer Inc.'s vaccine unit. (BioWorld Today) Read More

Aiming for Profitability, Nanogen Signs Merger Deal with Elitech

Oxford BioMedica Rejects 'Surprise' GeneThera Offer

Prestwick's Xenazine Gains First U.S. OK for Huntington's

Metronomic Dosing Successful in NCI Prostate Cancer Vaccine Trial

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 5, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 2, 2026

Janssen Pharmaceutica reports new TMEM175 activators

BioWorld Science

Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...

Cancer specter looming, Abtect effect in UC wallops Abivax

BioWorld

Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...

EASL spotlight: TUNE-401 advances epigenetic silencing in HBV

BioWorld

Several presentations at EASL highlight a new generation of therapies coming into view, with the work from Tune Therapeutics Inc. standing out as one of the most...